Catalog No.
PHD84701
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human PML (Leu73-Leu418).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
MYL,Promyelocytic leukemia protein,TRIM19,PML,RNF71,RING finger protein 71,Protein PML,PP8675,Tripartite motif-containing protein 19
Purification
Purified by antigen affinity column.
Accession
P29590
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study., PMID:40397068
Molecular epidemiology of JC polyomavirus genotypes in PLWH from Turkey., PMID:40353955
Progressive multifocal leukoencephalopathy during 4 years of Palbociclib for advanced breast cancer with a history of follicular lymphoma patient., PMID:40259166
A first report of progressive multifocal leukoencephalopathy in childhood-onset NMOSD., PMID:40247675
A peek into the pipeline: Expert views on emerging therapies., PMID:40239631
LANA-Dependent Transcription-Replication Conflicts and R-Loops at the Terminal Repeats (TR) Correlate with KSHV Episome Maintenance., PMID:40161765
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial., PMID:40120616
T-bet+ CXCR3+ B cells drive hyperreactive B-T cell interactions in multiple sclerosis., PMID:40107244
Microbial Transglutaminase-The Food Additive, a Potential Inducing Factor in Primary Biliary Cholangitis., PMID:40005074
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial., PMID:39974075
Prolonged survival in HIV-associated Progressive Multifocal Leukoencephalopathy treated with Pembrolizumab: a case series on treatment and long-term follow-up., PMID:39971875
Sintilimab for treating progressive multifocal leukoencephalopathy caused by human polyomavirus 2 virus infection following allogeneic hematopoietic cell transplantation: a case report., PMID:39898889
Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study., PMID:39893751
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT., PMID:39814869
Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment., PMID:39767644
Diagnosing progressive multifocal leukoencephalopathy: Positive predictive value of CSF JC virus quantitative PCR and importance of recognizing suggestive neuroimaging findings., PMID:39764914
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome., PMID:39686558
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia., PMID:39584789
A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses., PMID:39567664
A Case of Progressive Multifocal Leukoencephalopathy Caused by Epcoritamab., PMID:39552980
Transient biopsy-proven progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS) in an elderly woman without known immunodeficiency: a case report., PMID:39521972
Combination of low-dose, long-term immunoglobulin and mirtazapine is effective in progressive multifocal leukoencephalopathy caused by JC virus infection., PMID:39394563
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis., PMID:39393045
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors., PMID:39385035
Progressive multifocal leukoencephalopathy in systemic lupus erythematosus treated with pembrolizumab., PMID:39304216
Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases., PMID:39226901
Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML., PMID:39213467
Progressive multifocal leukoencephalopathy in sarcoidosis successfully treated with pembrolizumab., PMID:39155352
Revealing patient characteristics and treatment outcomes among ultra-long users of biologics for psoriasis., PMID:39140237
Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy., PMID:39086476
Safety and effectiveness of disease-modifying therapies after switching from natalizumab., PMID:39054846
Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer., PMID:39054318
A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)., PMID:39036981
Atypical Presentation of a Patient With Progressive Multifocal Leukoencephalopathy., PMID:39022523
Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective., PMID:39002043
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study., PMID:38991170
Structural basis for potent neutralization of human respirovirus type 3 by protective single-domain camelid antibodies., PMID:38937429
Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres., PMID:38877721
Measurable Residual Disease Analysis by Flow Cytometry and Correlation With Molecular Measurable Residual Disease in Acute Promyelocytic Leukemia: A Real-World Prospective Study., PMID:38838353
Universal paramyxovirus vaccine design by stabilizing regions involved in structural transformation of the fusion protein., PMID:38821950
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial., PMID:38793748
Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient., PMID:38785483
Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry., PMID:38769981
Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification., PMID:38761670
Intact natalizumab pharmacokinetics is impacted by endogenous IgG4 concentration., PMID:38759421
Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum., PMID:38735204
Protein-Centric Analysis of Personalized Antibody Repertoires Using LC-MS-Based Fab-Profiling on a timsTOF., PMID:38662593
Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review., PMID:38640586
Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38., PMID:38496658
Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity., PMID:38459086
For research use only. Not for human or drug use.
